Zhaoke Ophthalmology Limited

SEHK:6622 Stock Report

Market Cap: HK$764.6m

Zhaoke Ophthalmology Management

Management criteria checks 3/4

Zhaoke Ophthalmology's CEO is Benjamin Li, appointed in Jan 2017, has a tenure of 7.42 years. total yearly compensation is CN¥17.35M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth HK$233.35K. The average tenure of the management team and the board of directors is 3.2 years and 3.3 years respectively.

Key information

Benjamin Li

Chief executive officer

CN¥17.4m

Total compensation

CEO salary percentage40.2%
CEO tenure7.4yrs
CEO ownership0.03%
Management average tenure3.2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Benjamin Li's remuneration changed compared to Zhaoke Ophthalmology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023CN¥17mCN¥7m

-CN¥385m

Sep 30 2023n/an/a

-CN¥433m

Jun 30 2023n/an/a

-CN¥480m

Mar 31 2023n/an/a

-CN¥444m

Dec 31 2022CN¥21mCN¥6m

-CN¥407m

Sep 30 2022n/an/a

-CN¥355m

Jun 30 2022n/an/a

-CN¥303m

Mar 31 2022n/an/a

-CN¥1b

Dec 31 2021CN¥39mCN¥6m

-CN¥2b

Sep 30 2021n/an/a

-CN¥2b

Jun 30 2021n/an/a

-CN¥3b

Mar 31 2021n/an/a

-CN¥2b

Dec 31 2020CN¥3mn/a

-CN¥727m

Compensation vs Market: Benjamin's total compensation ($USD2.39M) is above average for companies of similar size in the Hong Kong market ($USD233.08K).

Compensation vs Earnings: Benjamin's compensation has been consistent with company performance over the past year.


CEO

Benjamin Li (61 yo)

7.4yrs

Tenure

CN¥17,354,000

Compensation

Dr. Xiaoyi Li, also known as Benjamin, Ph.D. is Founder of Lee's Pharmaceutical Holdings Limited and serves as its Executive Director & Senior Adviser since April 29, 2021. He serves as the Chief Executive...


Leadership Team

NamePositionTenureCompensationOwnership
Xiaoyi Li
Chairman of the Board & CEO7.4yrsCN¥17.35m0.031%
CN¥ 233.4k
Xiangrong Dai
COO & Executive Directorless than a yearCN¥1.82mno data
Lit Fui Lau
President & Chief Scientific Officer5.2yrsno datano data
Yang Lei
Group General Counsel2.7yrsno datano data
Mauro Bove
Senior Vice President of Corporate Development5.4yrsno datano data
Jiang Feng
Senior Vice President of Sales & Marketing2.4yrsno datano data
Albert Tsai
Chief Medical Officer3yrsno datano data
Guohui Zhang
Senior Vice President of Manufacturing & Logistics2.4yrsno datano data
Carol Liu
Group Head of Regulatory Affairs3.4yrsno datano data
Suk Yan Yau
VP of Financial Dept. & Company Secretary4.8yrsno datano data

3.2yrs

Average Tenure

49yo

Average Age

Experienced Management: 6622's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xiaoyi Li
Chairman of the Board & CEO7.4yrsCN¥17.35m0.031%
CN¥ 233.4k
Xiangrong Dai
COO & Executive Director3.7yrsCN¥1.82mno data
Yuk Lam Lo
Independent Non-Executive Director3.2yrsCN¥422.00kno data
Hin Wing Wong
Independent Non-Executive Director3.2yrsCN¥422.00kno data
Tiantian Zhang
Non Executive Director3.3yrsCN¥422.00kno data
Fui Kiang Liew
Independent Non-Executive Director2yrsCN¥422.00kno data
Leelalertsuphakun Wanee
Non-Executive Director7.3yrsCN¥422.00k0.0043%
CN¥ 33.0k

3.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 6622's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.